Open Access
Open access
,  том 46 ,  издание 1 ,  страницы 148-158

First-in-human study of 177Lu-EB-PSMA-617 in patients with metastatic castration-resistant prostate cancer

Тип публикации: Journal Article
Дата публикации: 2018-08-08
БС1
SJR: 2.28
CiteScore: 15.6
Impact factor: 8.6
ISSN: 16197070, 16197089
General Medicine
Radiology, Nuclear Medicine and imaging
Краткое описание
This translational study is designed to assess the safety, dosimetry and therapeutic response to a single, low-dose of 177Lu-EB-PSMA-617 in comparison to 177Lu-PSMA-617 in patients with mCRPC. Following institutional review board approval and informed consent, nine patients with mCRPC were recruited. Four patients accepted intravenous injection of 0.80–1.1 GBq (21.5–30 mCi) of 177Lu-EB-PSMA-617, then underwent serial whole-body planar and SPECT/CT imaging at 2, 24, 72, 120 and 168 h. The other five patients accepted intravenous injection of 1.30–1.42 GBq (35–38.4 mCi) 177Lu-PSMA-617, then underwent the same imaging procedures at 0.5, 2, 24, 48, and 72 h. All patients were evaluated by 68Ga-PSMA-617 PET/CT before and one month after the treatment. Dosimetry evaluation was compared in both patient groups. When the bone metastasis tumors with comparable baseline SUVmax in the range of 10.0–15.0 were selected from the two groups for comparison, the accumulated radioactivity of 177Lu-EB-PSMA-617 was about 3.02-fold higher than that of 177Lu-PSMA-617. Imaging dose of 177Lu-EB-PSMA-617 treatment showed significant decrease of 68Ga-PSMA-617 uptake within a month, which was not observed in patients imaged with 177Lu-PSMA-617 (SUV change: −32.43 ± 0.14% vs. 0.21 ± 0.37%; P = 0.002). 177Lu-EB-PSMA-617 also had higher absorbed doses in the red bone marrow and kidneys than 177Lu-PSMA-617 (0.0547 ± 0.0062 vs. 0.0084 ± 0.0057 mSv/MBq for red bone marrow, P < 0.01; 2.39 ± 0.69 vs. 0.39 ± 0.06 mSv/MBq for kidneys, P < 0.01). This first-in-human study demonstrated that 177Lu-EB-PSMA-617 had higher accumulation in mCRPC and that low imaging dose appears to be effective in treating tumors with high 68Ga-PSMA-617 uptakes. Elevated uptakes of 177Lu-EB-PSMA-617 in kidneys and red bone marrow were well tolerated at the administered low dose. Further investigations with increased dose and frequency of administration are warranted.
Для доступа к списку цитирований публикации необходимо авторизоваться.
Для доступа к списку профилей, цитирующих публикацию, необходимо авторизоваться.

Топ-30

Журналы

2
4
6
8
10
12
14
16
European Journal of Nuclear Medicine and Molecular Imaging
15 публикаций, 13.27%
Cancers
7 публикаций, 6.19%
Journal of Nuclear Medicine
6 публикаций, 5.31%
Pharmaceuticals
6 публикаций, 5.31%
Journal of Medicinal Chemistry
6 публикаций, 5.31%
Molecular Pharmaceutics
5 публикаций, 4.42%
EJNMMI Research
3 публикации, 2.65%
Molecular Imaging and Biology
3 публикации, 2.65%
International Journal of Molecular Sciences
2 публикации, 1.77%
Pharmaceutics
2 публикации, 1.77%
Bioconjugate Chemistry
2 публикации, 1.77%
ChemMedChem
2 публикации, 1.77%
bioRxiv
2 публикации, 1.77%
Molecular Cancer Therapeutics
2 публикации, 1.77%
Frontiers in Oncology
2 публикации, 1.77%
Bioorganic Chemistry
2 публикации, 1.77%
Russian Chemical Reviews
1 публикация, 0.88%
Cancer Biotherapy and Radiopharmaceuticals
1 публикация, 0.88%
Clinical Nuclear Medicine
1 публикация, 0.88%
Molecules
1 публикация, 0.88%
Frontiers in Molecular Biosciences
1 публикация, 0.88%
Biomedicines
1 публикация, 0.88%
Nuclear Medicine and Molecular Imaging
1 публикация, 0.88%
Translational Oncology
1 публикация, 0.88%
Advanced Drug Delivery Reviews
1 публикация, 0.88%
Seminars in Nuclear Medicine
1 публикация, 0.88%
Bioorganic and Medicinal Chemistry
1 публикация, 0.88%
Materials Today Advances
1 публикация, 0.88%
Nuclear Medicine and Biology
1 публикация, 0.88%
2
4
6
8
10
12
14
16

Издатели

5
10
15
20
25
30
Springer Nature
26 публикаций, 23.01%
MDPI
20 публикаций, 17.7%
American Chemical Society (ACS)
17 публикаций, 15.04%
Elsevier
14 публикаций, 12.39%
Wiley
7 публикаций, 6.19%
Society of Nuclear Medicine
6 публикаций, 5.31%
Ovid Technologies (Wolters Kluwer Health)
3 публикации, 2.65%
Frontiers Media S.A.
3 публикации, 2.65%
openRxiv
2 публикации, 1.77%
American Association for Cancer Research (AACR)
2 публикации, 1.77%
Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii
1 публикация, 0.88%
Mary Ann Liebert
1 публикация, 0.88%
Neoplasia Press
1 публикация, 0.88%
Taylor & Francis
1 публикация, 0.88%
Edizioni Minerva Medica
1 публикация, 0.88%
Proceedings of the National Academy of Sciences (PNAS)
1 публикация, 0.88%
AIP Publishing
1 публикация, 0.88%
XMLink
1 публикация, 0.88%
Tomsk Cancer Research Institute
1 публикация, 0.88%
Bentham Science Publishers Ltd.
1 публикация, 0.88%
Radiological Society of North America (RSNA)
1 публикация, 0.88%
Annual Reviews
1 публикация, 0.88%
5
10
15
20
25
30
  • Мы не учитываем публикации, у которых нет DOI.
  • Статистика публикаций обновляется еженедельно.

Вы ученый?

Создайте профиль, чтобы получать персональные рекомендации коллег, конференций и новых статей.
 Войти с ORCID
Метрики
113
Поделиться
Цитировать
ГОСТ |
Цитировать
Zang J. et al. First-in-human study of 177Lu-EB-PSMA-617 in patients with metastatic castration-resistant prostate cancer // European Journal of Nuclear Medicine and Molecular Imaging. 2018. Vol. 46. No. 1. pp. 148-158.
ГОСТ со всеми авторами (до 50) Скопировать
Zang J., Fan X., Wang H., Liu Q., WANG J., Li H., Li F., Jacobson O., Niu G., Zhu Z., Chen X. First-in-human study of 177Lu-EB-PSMA-617 in patients with metastatic castration-resistant prostate cancer // European Journal of Nuclear Medicine and Molecular Imaging. 2018. Vol. 46. No. 1. pp. 148-158.
RIS |
Цитировать
TY - JOUR
DO - 10.1007/s00259-018-4096-y
UR - https://doi.org/10.1007/s00259-018-4096-y
TI - First-in-human study of 177Lu-EB-PSMA-617 in patients with metastatic castration-resistant prostate cancer
T2 - European Journal of Nuclear Medicine and Molecular Imaging
AU - Zang, Jie
AU - Fan, Xinrong
AU - Wang, Hao
AU - Liu, Qingxing
AU - WANG, JINGNAN
AU - Li, Hui
AU - Li, Fang
AU - Jacobson, Orit
AU - Niu, Gang
AU - Zhu, Zhaohui
AU - Chen, Xiaoyuan
PY - 2018
DA - 2018/08/08
PB - Springer Nature
SP - 148-158
IS - 1
VL - 46
PMID - 30090965
SN - 1619-7070
SN - 1619-7089
ER -
BibTex |
Цитировать
BibTex (до 50 авторов) Скопировать
@article{2018_Zang,
author = {Jie Zang and Xinrong Fan and Hao Wang and Qingxing Liu and JINGNAN WANG and Hui Li and Fang Li and Orit Jacobson and Gang Niu and Zhaohui Zhu and Xiaoyuan Chen},
title = {First-in-human study of 177Lu-EB-PSMA-617 in patients with metastatic castration-resistant prostate cancer},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2018},
volume = {46},
publisher = {Springer Nature},
month = {aug},
url = {https://doi.org/10.1007/s00259-018-4096-y},
number = {1},
pages = {148--158},
doi = {10.1007/s00259-018-4096-y}
}
MLA
Цитировать
Zang, Jie, et al. “First-in-human study of 177Lu-EB-PSMA-617 in patients with metastatic castration-resistant prostate cancer.” European Journal of Nuclear Medicine and Molecular Imaging, vol. 46, no. 1, Aug. 2018, pp. 148-158. https://doi.org/10.1007/s00259-018-4096-y.
Ошибка в публикации?